Author:
Yang Jiani,Zhu Xingmei,Yuan Panpan,Liu Jiping,Wang Bin,Wang Guoquan
Funder
National Natural Science Foundation of China
Natural Science Foundation of Shaanxi Province
Youth fund of shaanxi university of traditional Chinese medicine
Team fund of shaanxi university of traditional Chinese medicine
Publisher
Springer Science and Business Media LLC
Reference27 articles.
1. Barta JA, Powell CA, Wisnivesky JP (2019) Global epidemiology of lung cancer. Ann Global Health 85(1):8–53
2. Christy WS, Tong WKKW (2017) Drug combination approach to overcome resistance to EGFR tyrosine kinase inhibitors in lung cancer. Cancer Lett 405(1):100–110
3. Uchibori K et al (2017) Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer. Nat Commun 8(1):14768–14800
4. Yang Dan TG (2009) Experimental research progress of traditional Chinese medicine in the treatment of lung cancer. Chin J Ttradit Chin Med 34(18):2405–2409
5. Xianzhong L (2019) Clinical observation of chemotherapy combined with traditional Chinese Medicine in the treatment of 35 elderly patients with advanced non-small cell lung cancer. J Qiannan Med College National 32(01):25–27